RxDoctor Payments Data

Jack Hydrick

Family · Murfreesboro, TNNPI 1053382648

Payments from drug & device makers

$9,007in general payments, 2019–2025

Across 441 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$808
  • Pfizer$782
  • Biohaven Pharmaceutical Holding Company Ltd.$771
  • Novo Nordisk$720
  • Otsuka America Pharmaceutical, Inc.$642
  • plus $4K from 32 others

What the payments were for

  • Travel & lodging$3544%
  • Food & beverage$8,65296%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,007 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,802
Medicare patients
163
Services billed
913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$54,347
OzempicSemaglutide18$22,097
AuvelityDextromethorphan Hbr/Bupropion11$13,294
EliquisApixaban11$8,614
BelsomraSuvorexant11$5,443
OxycontinOxycodone Hcl12$3,643
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$1,701
Bupropion XlBupropion Hcl27$1,321
Rosuvastatin Calcium76$1,301
Pregabalin42$1,177
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$1,130
ProgesteroneProgesterone, Micronized14$1,012
Armodafinil15$881
Np ThyroidThyroid,pork11$821
Duloxetine Hcl34$788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$559$54,34748 claims
Novo NordiskOzempic$720$22,09718 claims
Axsome Therapeutics, Inc.Auvelity$477$13,29411 claims
PfizerEliquis$782$8,61411 claims
MerckBelsomra$26$5,44311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →